An Introduction to Dermatological Cancers
The past decade has seen significant advances in the treatment landscape of melanoma. Therapies targeting the BRAF oncoprotein pathway and the development of immunotherapies have transformed the standard of care for patients.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Dermatological Cancers Content
Connecting Symptoms to Quality of Life: The Importance of Considering Patient Wellbeing when Managing Cutaneous T-Cell Lymphoma (CTCL)
Healthcare professionals are asked to report any adverse events via their national reporting system (see Section 4.8 of SmPC). In the UK reporting forms and information can be found at
or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Kyowa Kirin Ltd on +44 (0)1896 664000, email: firstname.lastname@example.org
Ryan Sullivan, AACR 2023: The STARBOARD phase III trial, encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma
The STARBOARD trial will investigate encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma. In this touchONCOLOGY interview, we speak with Dr Ryan Sullivan (Mass General Cancer Center, Boston, MA, USA) to discuss the mechanisms of encorafenib, binimetinib and pembrolizumab, as well as details on the STARBOARD trial. The presentation entitled […]
Ryan Sullivan, AACR 2023: Current therapeutic options for BRAF V600 mutated melanoma
Multiple therapies that have been approved for the treatment of BRAF V600 mutated melanoma. In this touchONCOLOGY interview, we speak with Dr Ryan Sullivan (Mass General Cancer Center, Boston, MA, USA) to discuss the current treatment paradigm and its limitations. Ryan Sullivan presented an abstract entitled ‘Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + […]
Georgina Long, ESMO 2022: Highlights in melanoma – SWOG S1801 trial investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma
Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss clinical trial highlights in melanoma presented at EMSO 2022. She highlights the SWOG S1801 trial, investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma, concluding use of a single-agent pembrolizumab, neoadjuvant therapy improves event-free survival compared to adjuvant therapy in high-risk resectable […]
Georgina Long, ESMO 2022: CheckMate 915 study – The use of ctDNA as a biomarker for predicting outcomes for adjuvant melanoma
In patients with resectable melanoma, circulating tumor DNA (ctDNA) detection post-resection may be useful to inform disease state and recurrence risk. Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss CheckMate 915 study and what it taught us about the use of nivolumab plus ipilumab in the adjuvant treatment of melanoma, and […]
Recognizing mycosis fungoides, a heterogeneous and challenging cutaneous T-cell lymphoma
Watch this activity to learn more about mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) and a new MF-CTCL online resource. Visit MF-Talks for more information.
Optimizing the patient journey in CSCC through multidisciplinary collaboration
In this activity, leading experts discuss optimal approaches for the management of patients with CSCC and consider how effective multidisciplinary collaboration can contribute to improved outcomes.
- Define multidisciplinary best practices for diagnostic workup of cutaneous squamous cell carcinoma (CSCC) and identification of risk factors influencing prognosis
- Outline interdisciplinary eligibility criteria for surgery and radiotherapy in patients with CSCC
- Determine the optimal use of systemic therapies in patients with unresectable locally advanced or metastatic CSCC and the role of the multidisciplinary tumour board in sharing clinical decisions in cancer care
Lymphocyte-activation Gene 3 and Programmed Cell Death 1 Checkpoint Inhibition as a Novel Combination in Advanced Melanoma
touchREVIEWS in Oncology & Haematology. 2021;17(2):58–9 DOI: https://doi.org/10.17925/OHR.2021.17.2.58
RELATIVITY-047 reported on the initial efficacy and safety of relatlimab (RELA), an antibody to lymphocyte-activating gene 3 (LAG-3), in combination with nivolumab (NIVO), an antibody to programmed cell death 1 (PD-1).1 These positive findings add to the existing evidence for the efficacy of anti-PD-1 therapy – either alone or in combination with ipilimumab (IPI), an antibody […]
Navigating the emerging complexities of melanoma treatment: New insights for clinical practice
Watch leading experts discuss evolving neoadjuvant, adjuvant and metastatic treatment options for patients with melanoma, taking in the latest data presented at the ESMO Congress 2021.
- Describe the long-term survival results in patients with melanoma and their relevance to treatment decisions
- Evaluate current strategies to improve outcomes for patients with melanoma who do not experience a durable response
- Recall the latest data for emerging treatment options, including the use of triple combination approaches, and how these therapies fit into the melanoma treatment paradigm